Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM27M in Advanced or Metastatic Solid Tumors
NCT05235438Phase 1Unknown
- Sponsor
- ImmuneOnco
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMM27M in solid tumor (advanced stage) and metastatic solid tumor, sponsored by ImmuneOnco. Primary endpoints: Dose-Limiting Toxicity at 3 weeks, Maximum Tolerated Dose and Recommended Dose for Expansion at 3 weeks and 1 more. Status: unknown.
02
Drugs
IMM27M
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT05235438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235438.